

mRNA Cancer Vacs: Exclusive New Updates Unveiled by Scientific Pioneers at RNA Therapeutics 2017

Targeted delivery systems showcased at 8th annual industry summit on RNA Therapeutics next month

LONDON, ENGLAND, UNITED KINGDOM, January 23, 2017 /EINPresswire.com/ -- According to a leading UK financial institute, BioNTech RNA Pharmaceuticals, one of Europe's largest private Biotechs, has been named as one of the top 5 companies to watch in 2017.*

With hopes in being the first to develop and market the next generation disruptive immunotherapies, SMi Group will be welcoming their expertise at the 8th annual [RNA Therapeutics](#) conference when it returns to Central London on 22nd and 23rd February.

Day One will feature a keynote from BioNTech Vice President, RNA Biochemistry & Manufacturing, Andreas Kuhn. The talk will present new developments into the first clinical experience using mRNA based cancer immunotherapy, as well as explore regulatory frameworks and GMP manufacturing.

In addition to chairing Day Two of the conference, Henrich Haas, BioNTech's Vice President of RNA Formulation & Drug Delivery, will be providing case study insight into RNA-Lipoplexes in a presentation looking at intravenously injectable RNA Nanomedicines as Cancer Vaccines. With a progressive outlook into nucleic acid based nano-medicines, the talk will delve deeper into topics such as RNA delivery technologies, medical challenges, clinical testing and manufacturing.

“

I'm interested in hearing about all the various technologies under development to address the delivery challenges for the different classes of RNA therapeutics”

Carpmaels & Ransford

Other notable speakers on the [programme](#) for RNA Therapeutics 2017 include:

- Nagy Habib, Head of Surgery, Co-Founder, Imperial College

Healthcare NHS Trust, MiNA Therapeutics

- Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
- Jeffrey Ulmer, Head of Pre-Clinical Research & Development, GSK Vaccines USA
- David Giljohann, CEO, Excicure



- Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
- Amotz Shemi, CEO, Silenseed
- Sanyogitta Puri, Associate Principal Scientist, AstraZeneca

Further information including a full speaker line-up and conference agenda is available online at www.therapeutics-rna.com

8th Annual Event: RNA Therapeutics 2017

Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb

Cophorne Tara Hotel, Kensington, London, UK

--- end ---

* Source:

<http://labiotech.eu/jpmorgan-european-biotech-2017>

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

For delegate inquiries contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk

To sponsor or speak, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.